Moderna’s (NASDAQ:MRNA) Q4 Earnings Results: Revenue In Line With Expectations But Full-Year Sales Guidance Misses Expectations Significantly
Biotechnology company Moderna (NASDAQ:MRNA) met Wall Street’s revenue expectations in Q4 CY2024, but sales fell by 65.6% year on year to $966 million. On the other hand, the company’s full-year revenue guidance of $2 billion at the midpoint came in 9.8% below analysts’ estimates. Its GAAP loss of $2.91 per share was 6.7% below analysts’ consensus estimates.